The consensus narrative frames Merck as a one-product company facing an existential patent cliff in 2028. Wefundamentally disagree with this characterization. Merck is executing one of the most ...

Bob Herman covers health insurance, government programs, hospitals, physicians, and other providers — reporting on how money influences those businesses and shapes ...

MedImpact expands access and affordability across healthcare with a low-cost alternative to one of the most prescribed and expensive biologics in the US MedImpact Holdings, Inc. today announced the ...

The product is priced at 95% below the brand-name cost. Ease of adoption. The product is FDA-designated as interchangeable and supported by innovative prescriber and patient engagement programs to ...

They are calling it crotchgate and penisgate. Winter Olympic ski jumpers are reportedly under scrutiny after two Norwegian ski jumping officials were suspended in January for claims of improperly ...

The last time I spoke about AbbVie Inc. (ABBV) it was in a Seeking Alpha article entitled as "AbbVie: Increased Outlook For 2025 And Expansions Merit Continued 'Strong Buy' Rating." For this article I ...

Shares of AbbVie (ABBV) lost ~7% on Wednesday after the Chicago-based pharma giant posted better-than-expected Q4 2025 results, which, according to BNP Paribas, were driven by its older blockbuster ...

Mounjaro (tirzepatide) is prescribed to manage blood sugar levels in people with type 2 diabetes. It’s available as a single-dose prefilled pen. You will administer your Mounjaro injections into your ...

It's refreshing when a leading AI company states the obvious. In a detailed post on hardening ChatGPT Atlas against prompt injection, OpenAI acknowledged what security practitioners have known for ...

Derek Lunsford addressed a dangerous rumor circulating within the bodybuilding community. On Dec. 17, 2025, he denied using PMMA injections (polymethyl methacrylate) and said he doesn’t even know what ...

AbbVie ABBV is a dominant player in the immunology space, powered by three blockbuster drugs — Skyrizi, Rinvoq and Humira — which together account for nearly half of its top line. Although the company ...